<DOC>
	<DOCNO>NCT01480739</DOCNO>
	<brief_summary>Study healthy volunteer see effect AZD5069 placebo neutrophil number function ( phagocytosis oxidative burst ) circulation , follow burst strenuous exercise follow subcutaneous injection granulocyte-colony stimulate factor ( G-CSF )</brief_summary>
	<brief_title>AZD5069 Neutrophil Function Study</brief_title>
	<detailed_description>A Randomised , Double-blind , Placebo-Controlled , Two-way Cross-over , Single Centre Study Healthy Subjects Assess Effect Oral Dosing AZD5069 Neutrophil Number Function Peripheral Blood Ability Recruit Neutrophils Circulation Exercise Subcutaneous</detailed_description>
	<criteria>Healthy Caucasian male postmenopausal/surgical sterile female , age 18 45 year inclusive screen Only woman nonchildbearing potential include study , ie , woman permanently surgically sterilise postmenopausal Nonsmokers exsmokers smoke history last 12 month prior Visit 1 smoke history le 10 pack year ( 1 pack year = tobacco consumption correspond 20 cigarette smoke per day 1 year ) screening Body mass index ( BMI ) &gt; 18 kg/m2 ≤30 kg/m2 minimum weight 50 kg Subjects history active latent tuberculosis ( TB ) , close contact anybody active TB Subjects history malignancy neoplastic disease ( except successfully treat basal squamous cell carcinoma skin ) Subjects pyrexial body temperature great 37.7 C Visit 2 , judge Investigator Alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) level ≥1.5 x upper limit normal ( ULN ) screening ( Visit 2 ) Peripheral blood neutrophil laboratory reference range screening ( Visit 2 ) hsCRP upper limit laboratory reference range Visit 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase 1 , AZD5069 , safety tolerability , healthy volunteer ,</keyword>
</DOC>